Researchers in Prof. Aaron Hsueh's laboratory have discovered a technique to promote fertility by stimulating the growth of ovarian follicles (functional units that produce oocytes) through disrupting the Hippo signaling pathway.
Researchers in the laboratories of Prof. Stanley Cohen and Prof Tzu-Hao Cheng have discovered that Supt4h is a potential therapeutic target for reducing toxicity and restoring the functionality of deleterious proteins in Huntington's (HD) and other polyQ diseases.
Dr. Stanley Cohen and colleagues have identified small molecular compounds that may be useful in the treatment of nucleotide repeat diseases. A well-known nucleotide repeat disorder is Huntington's disease.
Multiple Sclerosis (MS) is a potentially disabling autoimmune disease whereby autoactivated T and B cells attack and destroy protective myelin sheaths of the central nervous system(CNS).
Stanford researchers have developed a novel technique to control proton beams for radiation therapy to deliver a very high, full dose across a tumor in less than one second.
Researchers at Stanford and the Chan Zuckerberg Biohub have developed a platform for characterizing a population of microbes using spectrally encoded beads.
Stanford researchers at the Okamura Lab have prototyped a computerized "pillow" that fits in the hand and uses air pressure to measure involuntary grip force (spastic hypertonia).
Researchers at Stanford have developed a microparticle-based vaccine that in a single shot enables enhanced activation of CD8+ and/or CD4+ T cells to fight against infectious diseases and cancer.
Stanford researchers are investigating a new method and possible apparatus for neurostimulation of the cochlea for restoration of hearing while minimizing damage to residual hearing.
Stanford researchers have used deep learning to create a radiotherapy treatment plan verification algorithm. Patient specific dose verification is traditionally done by checking the dose in a patient-mimicking phantom or by using an independent dose calculation algorithm.
Researchers at Stanford and the Chan Zuckerberg Biohub have discovered cross reactive, broadly neutralizing human antibodies against all serotypes of dengue virus.